Industry News

Ibrutinib for the Treatment of Adult Patients with CLL/SLL

Ibrutinib (Imbruvica^®, Pharmacyclics) is a once-daily oral therapy indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Ibrutinib is also indicated for the treatment of adult patients with CLL/SLL with 17p deletion.

Read efficacy study and prescribing information.

To help guide and assist patients during treatment, Pharmacyclics the YOU&i^TM Support Program, which provides information on insurance coverage and out-of-pocket costs, and what to expect while on treatment.

Posted on 10/07/2020